Request full documentation of the protocol, the cell source, and the supervising clinicians credentials before committing
Examples include: Wound repair models that require fibroblast migration, extracellular matrix deposition, and remodeling Tendon/ligament repair models focused on cell survival, growth and restoration of tissue organization[1] Research in fibrosis and remodeling where thymosin beta-4 related pathways are of interest[2] Studies associated with angiogenesis (e.g., when vascular support is a limiting factor in tissue regeneration) [5] Since synergy is an outcome claim that must be demonstrated experimentally, it is hypothesized here: if BPC-157 and TB-500 affect different critical points of repair (e.g., gene expression versus cytoskeleton mobilization), combined administration in preclinical designs could produce additive or multiplicative improvements in migration rate, wound closure, tissue organization, or histological markers of remodeling, depending on the model and evaluation criteria
There is no insurance pathway for an adverse event
In a May interview with wellness entrepreneur Gary Brecka, Kennedy elaborated on how he sees the role of the FDA with regards to experimental treatments, including peptides
Growth promotion of Chinese cabbage and Arabidopsis by Piriformospora indica is not stimulated by mycelium-synthesized auxin
